The tumor microenvironment is now recognized as a major factor that influences not only the response to conventional anti-cancer therapies but also helps define the potential for malignant progression and metastasis. In particular, hypoxia is now considered a fundamentally important characteristic of the tumor microenvironment. Furthermore, discovery of the hypoxia inducible factor 1a a (HIF-1a a) has led to a rapidly increasing understanding of the molecular mechanisms involved in tumor hypoxia. This in turn has led to the current extensive interest in the signal molecules related to tumor hypoxia as potential molecular targets for cancer therapeutics. In this paper we give an overview of recent advances in hypoxia research, including cancer treatments that target tumor hypoxia. Progress in the development of hypoxia-targeting drugs will be discussed, including antiangiogenic hypoxic cell radiosensitizers and hypoxic cytotoxins, hypoxia targeting boron carriers and p53-inhibiting bifunctional radiosensitizers. We will also review our own recent research results in these areas. For example, we have found that certain of the 2-nitroimidazole radiosensitizers and heterocycle-N-oxide hypoxic cytotoxins we developed have antiangiogenic activity and antimetastatic activity. We propose that these activities are based on the inhibition of signal transduction mediated by HIF-1a a. The anti-tumor activities of hypoxia response are considered to be cytostatic (tumor dormancy-inducing) effects in contrast to cytotoxic DNA damaging effects. The combinaiton of these cytostatic effects that are related to radiosensitization with the cytotoxic effects of radiation should improve the prognosis and QOL of patients receiving radiation and lead to an overall response to treatment. Based on these considerations, we developed the antiangiogenic hypoxic cell radiosensitizers, TX-1877, TX-1898 and the hypoxic cytotoxin TX-402 that inhibits the HIF-1a a pathway We will also discuss our research involved with the development of other drugs to exploit tumor hypoxia, including a hypoxia-targeting boron carrier for boron neutron capture therapy (BNCT) and a p53 inhibiting radiosensitizer.
INTRODUCTION
As the molecular mechanisms behind tumor hypoxia have now been delineated, the important conclusion of the radiation oncologist Dr. Okuyama that "hypoxic milieu as the primary cancer environment" 1) needs to be reexamined for its impact on current cancer diagnosis and treatment. It is apparent that, although hypoxic tumor cells cannot live without oxygen and nutrients, aggressive tumor cells isolated far from blood still survive in spite of a low supply of these. Because of their low radiosensitivity these hypoxic tumor cells are recognized as a potential problem in radiotherapy and a predictor of poor prognosis and recurrence. Accordingly, development of hypoxic cell radiosnesitizers to enhance the radiosensitivity of tumor hypoxic cells has been a goal of medicinal chemists. However, to date there are no clinicallyavailable drugs with the exception of nimorazole, 2, 3) used locally in Denmark. 4) In the traditional paradigm of radiobiology, the design of radiosensitizers focused on the development of oxygen mimics that could partially compensate for the low oxygen environment to increase radiation-induced DNA damage. However, modern "molecular target-based hypoxic cell radiosensitizers" designed on the basis of the survival strategy of tumor cells in the tumor microenvironment 5, 6) would appear to be more promising candidates. In this review, we describe the current status of drug discovery research in radiotherapeutics. We include our own recent efforts on the development of molecular target-based hypoxic cell radiosensitizers and hypoxic cytotoxins that inhibit hypoxia adaptation mechanisms, including angiogenesis and metastasis, and discuss the prospects for future progress in this area.
DESIGN OF BIFUNCTIONAL ANTIANGIOGENIC HYPOXIC CELL RADIOSENSITIZERS; TX-1898 AND TX-1877
In nitroaromatic hypoxic cell radiosensitizers, the nitroimidazolyl unit can act as an oxygen-mimic to render irreversible the damage to DNA caused by ionizing radiation under hypoxic conditions. In addition, these compounds function as hypoxia markers for imaging of hypoxic cells, whereby the hydroxylamine derived by bioreductive metabolism reacts with intracellular nucleophiles and are retained as bioconjugates (Fig. 1) . [7] [8] [9] [10] Based on such hypoxic affinity of nitroimidazoles through their bioreductive activation, [
18 F]-fluorinated misonidazole was developed as a PET imaging agent for regional localization of hypoxia. 11) Recently, the cupper complex [ 64 Cu]Cu-ATSM, another hypoxic marker that uses the bioreduction mechanism, has received attention for PET imaging because of a higher level of accumulation. 12, 13) In this paper we will not discuss the history of development of nitroaromatic or nitroazole-type hypoxic cell ra- diosensitizers because of the many review papers and books available on this subject. 8, 14) We do list here 2-nitroimidazole hypoxic cell radiosensitizers such as KU-2285 and doranidazole, 15) 5-nitroimizazole derivatives such as nimorazole, 4) and the nitrotriazole derivative, sanazole 3, 16) that are undergoing clinical trials (Fig. 2) . All of these candidates except nimorazole were developed in Japan. 17) In the long and suspenseful history of research with hypoxic radiosensitizers the unsuccessful clinical trials of misionidazole (MISO) and etanidazole decreased the enthusiasm for this approach. It is to be hoped that clinical trials with these new agents will produce good results so that development of radiosensitisers can be re-established as a promising strategy for clinical cancer therapy.
Design of Hypoxia-Targeting Drugs as New Cancer Chemotherapeutics
We have designed new bifunctional radiosensitizers that are based on the previously demonstrated effectiveness of nitroaromatics as hypoxia-targeting moieties. TX-1845 and TX-1846 are 2-nitroimdazole derivatives containing a haloacetylcarbamoyl group as an acceptor of intracellular nucleophiles such as mercapto and amino groups (Fig. 3) . 18, 19) These bifinctional radiosensitizers are designed to cross-link with DNA or proteins in the hypoxic condition by bioreductive activation. Another bifunctional radiosensitizer developed by Adams, RSU-1069, having an aziridine side-chain, as well as its prodrug RB-6145, showed enhanced hypoxic cytotoxicity ascribed to such bioalkylating units. 20, 21) Our haloacetylcarbamoyl compounds showed 100 times higher hypoxic cell radiosensitizing potency than did MISO and also showed anti-angiogenetic activities in the CAM assay (Table 1) . In contrast, their corresponding alcohol intermediates, TX-1831, 1832, and MISO showed low radiosensitizing effects, but no anti-angiogenetic activity. These results suggested that the haloacetylcarbamoyl group might contribute to the anti-angiogenetic activity through an inhibition of proteases such as matrix metalloprotease (MMP). When we compared angiogenesis inhibition and the inhibition of porcine pancreatic elastase between enantiomers, TX-1898 and TX-1900, the R-isomer, TX-1898 proved to be more potent in each assay. 18) Another hypoxic cell radiosensitizer, KIN-806 having a methylacetamide side-chain, showed metastasis inhibition and biological response modifying (BRM) activities. Based on these results, we designed and synthesized a series of acetamide compounds and evaluated them as hypoxic cell radiosensitizers. This led to the development of TX-1877, a compound that showed higher inhibitory activity against metastasis and angiogenesis and caused greater enhancement a) Drug concentration required to achieve an enhancement ratio of 1.6. of macrophage infiltration than did KIN-806 (Fig. 4) . 22, 23) It is noteworthy that TX-1877 alone showed in vivo antitumor activity in the absence of radiation. However, it is still unclear as to which, if any, of these various activities relate to each other.
To summarize, in our strategy for the design of bifunctional hypoxic cell radiosensitizers, the nitroaromatic group, which is a proven radiosensitizing and hypoxia targeting functionality, is linked to an acetamide side-chain moiety, which controls pharmacokinetics and toxicity and gives additional biological response modifying effects (Fig. 5 ). This molecular design allowed us to develop the first hypoxic cell radioasensitizer that also inhibited tumor hypoxia responses such as angiogenesis and metastasis. Side chain modifications afforded more potent antitumor agents, such as TX-1845, TX-1846, TX-1898, and TX-1877. The inhibition of hypoxia responses by these agents is thought to result in a cytostatic (tumor dormancy-inducing) effect in contrast to a cytotoxic DNA damaging effect. The cytostatic effects exhibited by these compounds thus should act together with their ability to sensitize tumor cells to the cytotoxic effects of radiation to improve the prognosis and QOL of patients. We feel this could result in achievement of an overall better outcome of treatment.
DENDRIMERIC ENDOSTATIN ANALOG; TX-1944
The recent impressive results from clinical trials of such antiangiogenic drugs as bevacizumab and sorafenib suggest the possibility of antiangiogenic therapy as a general strategy for cancer treatment. 24) These drugs exert cytostatic effects that induce tumor dormancy. Worldwide there are currently approximately 100 such candidate drugs undergoing clinical trials. As discussed above, angiogenesis is itself an adaptation to hypoxia that is induced by signaling through the hypoxia inducible factor 1 (HIF1)-VEGF system (VEGF signaling system). 25, 26) There is also evidence for possible biological roles of heparin and heparan sulfate (HSPG) that are related to binding of VEGF and FGF-2 to endothelial cell surface receptors. 27, 28) In addition, X-ray analysis of an endogenous antiangiogenic factor, endostatin, revealed the existence of an arginine cluster with accumulated positive charge on its surface that probably binds to heparin and HSPG in competition with VEGF. 29, 30) Based on these finding we designed and synthesized the heparin-binding arginine dendrimer TX-1944 as a positive charge-rich arginine cluster mimic (Fig. 4) . TX-1944 exhibited antiangiogenic activity and inhibited endothelial cell proliferation, activities which were strongly correlated with its heparin-binding activity. The citruline dendrimer, TX-1993 (the arginine of TX-1944 is replaced with citruline) had weaker heparin-binding activity and a lower inhibitory effect on endothelial cell proliferation. TX-1944 containing 16 arginine residues had higher activities than the shorter chain-containing TX-1943 made up of 8 arginine residues. This result suggests that dendritic arginine residues mimicking the protein-surface is important for heparin-binding activity and angiogenesis inhibition. TX-1944 was introduced as an antiangiogenic agent based on new drug-design concept in the column "monitor: novel antitumor molecules" in Drug Discovery Today. 31) 4. DESIGN OF HYPOXIC CYTOTOXINS TX-402 4.1. Characteristics of Tumor Hypoxia and HypoxiaTargeting Antitumor Therapeutics Living beings can recognize changes to their external environment and adapt to these changes. Thus, they have the ability to survive and evolve in a variety of stressful environments. The adaptation reactions to such environmental stress occur not only physiologically but also at a cellular level. Currently, the mechanisms of cellular adaptation are more and more being delineated at the molecular level. Oxygen is an especially impor- , allowing it to be recognized by a protein-ubiquitin ligase complex containing von Hippel-Lindau tumour suppressor protein (pVHL), and leading to polyubiquitinated HIF-1a degradation by the proteasome. In hypoxia, PHDs activities are low because of O 2 depletion, which leads to HIF-1a accumulation and translocation to the nucleus. There, HIF-1a interacts with HIF-1b to make a heterodimer complex that binds to hypoxia-response elements (HREs) within the promoters of target genes and recruits transcriptional co-activators such as p300/CBP for full transcriptional activity. The activation of the downstream hypoxia stress response genes completes the hypoxia adaptation.
tant environmental factor for most living things (including human beings) on the earth and oxygen-dependent living systems must adapt in order to survive deprivation of oxygen (hypoxia). It is well known that the activation of glycolysis and induction of angiogenesis is a normal adaptive reaction in response to hypoxic stress. Such reactions are actually consistent in character with the cellular responses that occur in the hypoxic tumor microenvironment. In addition to tumors, the limited examples of other hypoxia-related diseases include acute or chronic ischemia and chronic obstructive pulmonary disease, age-related macular degeneration and diabetic retinopathy.
The hypoxia-response signaling system involves the transcription factor hypoxia-inducible factor-1 (HIF-1) that is activated by hypoxic stress. Our current understanding of this system was recently enhanced by discovery that prolyl hydroxylase (PHD) functions as an oxygen sensor. [32] [33] [34] HIF1a plays a pivotal role in cellular adaptation to hypoxic stress (Fig. 5) . In normoxia, the HIF-1a subunit is targeted for destruction by prolyl hydroxylation, a specific modification that provides recognition for the E3 ubiquitin ligase complex containing the von Hippel-Lindau tumor suppressor protein (pVHL). However, since PHD requires oxygen as a co-substrate, hypoxia triggers accumulation of HIF-1a due to lower PHD activity and this, in turn, activates the downstream hypoxia stress response genes necessary to complete the hypoxia adaptation. The hypoxia inducible genes transcriptionally activated by HIF-1a have been identified as regulators of biological transformations such as glycolysis, cell proliferation, angiogenesis, apoptosis, immortalization, and metastasis. Cancer cells may promote the survival pathways (angiogenesis and immortalization, metastasis, and proliferation) preferentially over the death pathway (apoptosis) to construct the tumor specific microenvironment. 35, 36) As discussed above, hypoxia in living things is thought to be a solid tumor-specific condition and is termed the tumor microenvironment.
In modern approaches to anti-cancer therapy, many "change of idea"-inspired drug discovery strategies are attempting to turn conventional cancer treatments into more tumor-specific therapies. For example, in a new focus of research on tumor microenvironment-targeted cancer specific therapeutics, the troublesome characteristics of hypoxic cells, such as radio-and chemotherapeutic-resistance, are now being re-evaluated as tumor-specific factors that can be exploited. Accordingly, signal molecules related to tumor cell hypoxia response recently have become popular molecular targets. 35, 37, 38) Strategies of cancer therapeutics that target hypoxia include 1) radiation therapy plus hyperbaric oxygen and oxygen-mimic chemical modifiers, 2) therapeutics using tumor hypoxic microenvironmental factors, such as hypoxia, low pH, low glucose, and abnormal microcirculation, and hypoxia-related tumor signals. In the former strategies, radiation therapy plus hyperbaric oxygen and oxygen-mimic chemical modifiers have been employed to overcome radioresistant hypoxic cells during radiotherapy. 39) For example, procedures for hyperbaric oxygen therapy in combination with administration of nicotinamide (ARCON: accelerated radiotherapy with carbogen and nicotinamide) 40) and hypoxic cell radiosensitizers/hypoxic cytotoxins as oxygen-mimic chemical modifiers have been developed 8, 14) The latter approach has incorporated a wide variety of treatments, including hyperthermia, antiangiogenic therapy, hypoxia-selective bioreductive prodrugs (gene-directed enzyme-prodrug therapy (GDEPT) and tumor-activated prodrugs (TAP)) 41) inhibition of HIF-1a and related proteins, and gene therapy using transcriptional regulator of hypoxia response element (HRE).
TX-402: Hypoxic Cytotoxins Designed to Be Activated through Bioreduction in Hypoxic Cells for Suppression of the Hypoxia Response Pathway
As discussed above, hypoxic cell radiosensitizers and hypoxic cytotoxins are useful lead compounds for development of anticancer drugs because of their ability to function as bioreductive agents and tumor-targeting drugs. We describe in this section our strategies for the development of cytostatic antitumor drugs designed from hypoxia-targeting molecules and tumor hypoxic microenvironment modifiers.
Representative anticancer drugs activated by bioreduction include the nitroaromatics described above as well as quinones and heterocyle-N-oxides. 42) Denny et al. designed many interesting nitroaromatic prodrugs which are activated through bioreduction. 43, 44) Mitomycins are antineoplastic agents isolated from Streptomyces lavendulae that incorporate aziridine and quinone moieties in their structures. These are converted through a two-electron reduction to the active forms that function as DNA crosslinkers. 45) Mitomycins are naturally occurring prototypes of bioreductive anticancer prodrugs. Since their discovery, various reductively activated prodrugs have been developed based on the concepts revealed by these hypoxic cytotoxins. In addition many hypoxia-targeting hybrid drugs have been designed that incorporate quinones and nitroaromatics (triggers) connected to cytotoxic units (effectors) through linker units. Upon activation, such hybrid drugs are designed to release strong alkylating agents, for example cyclophosphoramide. 46) At present, the leading hypoxic cytotoxin is the benzotriazine-N-oxide, tirapazamine (TPZ), which has been shown to have high hypoxic cytotoxicity and has been promoted to clinical trials. 47, 48) TPZ is activated through a one-electron reduction to produce a hydroxyl radical that damages DNA (Fig. 6) . In hypoxic conditions, tirapazamine is reported to exert 50 to 300 times stronger cytotoxicity than in normoxic condition. Our studies have shown that TPZ can induce apoptosis at various effective concentrations in either hypoxic or normoxic conditions. The apoptosis occurred independently of p53 at low dose in hypoxic condition, while in normoxic conditions the apoptosis induced at high dose was partially p53-dependent. In comparison, a quinoxaline Noxide, TX-402, showed less normoxic cytotoxicity than TPZ but stronger hypoxic cytotoxicity. This suggests that TX-402 may be a more effective hypoxic cytotoxin than TPZ. 49) Furthermore, we have found that these heterocyclic aromatic hypoxic cytotoxins also prevented the hypoxia signal transduction pathway mediated by HIF-1a inhibition under hypoxic condition and inhibited angiogenesis significantly at a dose of 5 mg/CAM or greater in the chick embryo chorioallantoic membrane (CAM) assay. TX-402 and TPZ reduced HIF-1a protein dose-dependently (Fig. 7) and suppressed the induction of mRNA of Glut-1, Glut-3 and VEGF. 50) Their potent antiangiogenic effects can be attributed to the suppression of VEGF via their block of the HIF-1a pathway. Therefore, we are currently designing and synthesizing derivatives based TX-402 and TPZ with a focus on the HIF-1a inhibitory activity. Our goal is to develop new hypoxic cytotoxins that possess additional potent cytostatic biological effects including antiangiogenic and antimetastatic activities.
In a recent prodrug approach, these hypoxic cytotoxins were used in combination with suicide genes (gene-directed enzyme prodrug therapy: GDEPT). 51, 52) In the GDEPT strategy, the expression of a prodrug-activating redox enzyme gene in hypoxic condition selectively makes the bioreductive anticancer drugs cytotoxic and keeps the concentration of active species high and stable within hypoxic tumor cells, even in the heterogeneous tumor microenvironment. To achieve higher gene expression selectively in hypoxic regions, hypoxia response promoters containing the hypoxia response element (HRE) were designed and used to control the fusion gene expression through hypoxia-inducible factor-1 (HIF-1) pathway. 53, 54) 
DESIGN OF HYPOXIA-TARGETING HYBRID-TYPE BORON CARRIERS
Boron neutron capture therapy (BNCT) is a targeted radiation therapy that significantly increases the therapeutic ratio relative to conventional radiotherapeutic modalities. 55) BNCT is a binary system: A boron-10 ( 10 B)-labeled compound is administered that delivers high concentrations of 10 B to the target tumor relative to surrounding normal tissues. This is followed by irradiation with thermal neutrons or epithermal neutrons to develop a neutron capture reaction in boron [ 10 B (N, a) 7 Li]. The alpha and 7 Li particles released from the reaction cause damage within the diameter of one or two tumor cells (5-9 mm). Therefore, in principle BNCT should be very effective in destroying tumors selectively providing that a sufficient amount of 10 B can be accumulated in the target tumor and a sufficient number of very low-energy thermal neutrons can be delivered there. 56) For successful BNCT, the development of an efficient tumor-selective 10 B delivery agent is of pivotal importance. However, Sodium borocaptate (BSH), 57) which is one of the 10 B-carriers currently used clinically, is less effective on a solid tumor where hypoxic cells exist because of inefficient uptake into tumor cells, particularly into intratumor hypoxic cells, due to its hydrophilic character. 58) To address such problems, we designed hypoxia-targeting hybrid boron-carriers using a hydrophobic linker in order to improve uptake efficiency of the BSH molecule into the cells. To achieve hypoxia selectivity, hypoxic cytotoxins such as tirapazamine or TX-402 were conjugated and a 2-nitroimidazole moiety was incorporated as a hypoxic cell radiosensitizer. Thus, TX-2041, TX-2042, TX-2058, TX-2059, and TX-2060 were designed and synthesized as 2-nitorimidazole-BSH conjugates having an acetylcarbamoyl linker. In addition, TX-2091, TX-2095, TX-2097, TX-2100, and TX-2110 were synthesized as hypoxic cytotoxin-BSH conjugates from BSH and TX-402 with the haloacetylcarbamoyl group introduced on the amino group (Fig. 8) . The haloacetylcarbamoyl group of a synthetic intermediate showed high reactivity with BSH.
To evaluate the 2-nitroimidazole-BSH conjugates, each compound was administered intraperitoneally to tumor-bearing mice, and the 10 B concentrations in tumor, muscle, liver, and blood samples were measured. The results showed that TX-2060 maintained high 10 B concentrations in solid tumors more effectively than any other compound in this study, and did not produce high 10 B concentrations in the blood and liver. We next examined the radiosensitizing activity of TX-2060 during neutron beam irradiation. We found that the enhancement ratio (ER) values were significantly larger for TX-2060 than for BSH, not only in total tumor cells but also At 24 h after inoculation in glass petri dishes, TX-402 and TPZ were added at a dose of 40 mM, and then hypoxic conditions were maintained with mixed gas (1% or 0% O 2 , 5% CO 2 , and a balance of N 2 ) for 5 h.
in quiescent (Q) cells. 59) This suggests that 10 B from TX-2060 could be localized in hypoxia-rich Q cells more easily than that from BSH. Among the hypoxic cytotoxin-BSH conjugates, TX-2100 had the most favorable characteristics for concentrating a sufficient amount of 10 B in tumors and maintaining a high enough 10 B concentration during irradiation. TX-2100 also had a significantly higher radiosensitizing effect during neutron beam irradiation than did BSH, in spite of being administered at half the molar dosage of BSH (Fig.  9 ). Furthermore, with g-rays TX-2100 exhibited a clear radiosensitizing effect not only on total cells but also on Q and hypoxic tumor cells, an effect not seen with BSH. 60 ) From these results, we suggest our rationally designed hypoxia-targeting hybrid boron-carriers can accumulate in hypoxic cells to sensitize the neutron irradiation effect. We feel the strategy used in the design of these hypoxia-targeting hybrid boroncarriers should prove useful for the development of additional promising boron carriers for BNCT.
DESIGN OF P53 INHIBITING HYPOXIC CELL RA-DIOSENSITIZERS
Tumor suppressor protein p53, called "the guardian of the genome," is a transcription factor that activates DNA repair proteins, maintains cell cycle arrest, and initiates apoptosis to prevent genome mutation when DNA is damaged. However, p53 is inactivated or lost in the majority of human cancers resulting in disruption of these genome-stabilizing functions in the cells. 61) p53 is currently a target of emerging drug therapies directed toward neurodegenerative diseases such as Alzheimer's and Parkinson's disease, and for alleviation of side effects associated with cancer treatments. 62, 63) Cancer treatments that employ radiation and chemotherapeutic agents produce side effects related to p53 dependant signal transduction because of DNA damage to normal cells surrounding the tumor. Recently, 2-(2-imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolylethanone hydrobromide (PFTa, Fig. 10 ), was identified from a broad screen of 10000 compounds as an inhibitor of g-radiation-induced cell death. This protection by PFT-a has been attributed to inhibition of p53 transactivation. 64) Based on these findings, we initiated research to develop a hypoxic cell radiosensitizer that is capable of inhibiting p53 using PFT-a as a lead compound. A hybrid hypoxic cell radiosensitizer was envisioned that would combine p53 inhibition of PFT-a with a 2-nitroimidazole as a radiosensitizer. The hybrid structure thus is designed to improve the low linear energy transfer (LET) radiosensitivity of the hypoxic cell during radiotherapy, while at the same time to prevent side effects of radiation in normal cells. The p53-inhibiting hypoxic cell radiosensitizer should protect normal cells and sensitize hypoxic tumor cells when it is combined with radiation, thus improving the therapeutic ratio of radiotherapy.
Although a detailed structure-activity relationship concerning PFT-a is not clear at present, the 2-imino-4,5,6,7-tetrahydrobenzothiazole moiety of PFT-a was shown to be converted to the cyclic dehydrated form (PFT-b) in situ in the biological assay incubation medium. This was shown to have more potent p53 inhibitory activity than PFT-a (Fig. 10) . 65) In order to clarify the roles of PFT-a and PFT-b in p53 inhibition, we designed a PFT-a alcohol analog, TX-2120, which cannot form the cyclic dehydrated structure. We investigated the protective effects of PFT-a, PFT-b, and TX-2120 against p53 dependent heat-induced cell death using SAS/neo cell (wild-type p53). 66) Our results showed that the protective effects of PFT-a, PFT-b, and TX-2120 to apoptosis induced by heating were almost equal. This suggested that the dehydrating cyclization of PFT-a into PFT-b was not indispensable to the protective action resulting from p53 inhibitory activity. In order to introduce hypoxic cell radiosensitizing activity we next prepared TX-2004 wherein the methyl phenyl group of PFT-a is replaced with the 2-nitroimidazole group (Fig. 11) . The enhancement ratio (ER) of TX-2004 was 1.54 at a dose of 50 mM on H1299/wtp53 cell (wild-type p53), while that of PFT-a was 1.06 at 50 mM. In addition, TX-2004 showed a protective effect for heat-induced apoptosis on H1299/wtp53 cell 67) to the same degree as PFT-a. From these results we demonstrated that TX-2004 is a bifunctional molecule with hypoxic cell radiosensitizing activity and p53 inhibitory activity.
CONCLUSION
It has been more than a half-century since Thomlinson and Gray proposed the existence of hypoxic cells in tumor tissue. 68) Most research on tumor hypoxia had focused only on the study of radiosensitivity and the "oxygen effect" on hypoxic cells until the discovery of HIF-1a by Wang et al. in 1995. 69) Since then, the hypoxia microenvironment has been recognized as a major regulating factor in tumor proliferation and differentiation. This has spurred efforts in cancer research to achieve a greater understanding of tumor hypoxia on the molecular level. Research detailing hypoxia sensing mechanisms and adaptive pathways continue to define new molecular targets for cancer treatments and point to new drug discovery targets.
In this report we have reviewed recent advances of hypoxia research with a focus on our own recent results and perspectives on hypoxia-targeting drug development. With respect to hypoxic cell radiosensitizers, intense efforts by many scientists unfortunately to date have failed to produce a drug available for clinical use. However, from a global perspective, it is very encouraging that the 5-nitroimidazole radiosensitizer, nimorazole has been used with some success for the standard treatment of most head and neck cancer patients in Denmark. 4, 70) We indeed acknowledge and pay respect to the Danish clinical oncologists, Prof. Jens Overgaard et al. at Aarhus Univeristy Hospital, Aarhus, Denmark, in their promotion of this clinical trail. 71) We also desire to introduce our rationally designed hypoxia-targeting compounds for clinical use in the near future through cooperative research with basic scientists as well as clinical research scientists. 
